Axicabtagene ciloleucel (target antigen CD19) addresses B-cell non-Hodgkin lymphoma (NHL) and follicular lymphoma and is a second-line therapy for large B-cell lymphoma, with an estimated overall 2-year of 61% [19]. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.